Sexually transmitted infections (STIs) are a difficult health challenge for immunocompromised patients. Patients treated for several haematological malignancies have further compromised immune systems. Furthermore, many chemotherapies, alone or associated with haematopoietic stem-cell transplantation, make the body's natural barriers extremely fragile. STIs can negatively impact both patient morbidity and mortality. In this Series paper, we discuss Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis, human immunodeficiency virus, herpes simplex virus, human papilloma virus, and hepatitis B virus, as we found them to be associated with increased risks for haematological malignancy treatments, either by incidence or by severity. Protective measures and vaccines for patients with haematological malignancies are also discussed. Large, well conducted studies should be encouraged, with the aim to systematically analyse the impacts of STIs in patients with haematological malignancies, especially given the difficulties that antimicrobial resistance can confer to patient management.

中文翻译：

---

血液系统恶性肿瘤背景下的性传播感染


性传播感染 （STI） 是免疫功能低下患者面临的一项艰巨的健康挑战。接受多种血液系统恶性肿瘤治疗的患者进一步损害了免疫系统。此外，许多化疗，无论是单独使用还是与造血干细胞移植相关，都会使身体的天然屏障变得极其脆弱。STI 会对患者的发病率和死亡率产生负面影响。在本系列论文中，我们讨论了沙眼衣原体、淋病奈瑟菌、梅毒、人类免疫缺陷病毒、单纯疱疹病毒、人瘤病毒和乙型肝炎病毒，因为我们发现它们与血液系统恶性肿瘤治疗的风险增加有关，无论是发病率还是严重程度。还讨论了血液系统恶性肿瘤患者的保护措施和疫苗。应鼓励进行大规模、实施良好的研究，目的是系统分析性传播感染对血液系统恶性肿瘤患者的影响，特别是考虑到抗微生物药物耐药性可能给患者管理带来困难。